Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Merck R&D Renaissance To Continue With Three NDA Filings In 2007

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

During Dec. 12 investor meeting, Merck Research Labs President Peter Kim says firm will file NDAs for compounds to treat HIV, insomnia and atherosclerosis in 2007.

You may also be interested in...



Gilead’s Novel Integrase Inhibitor Could Enter Phase III In Second Half

Firm reports first-quarter revenues of over $1 billion.

Gilead’s Novel Integrase Inhibitor Could Enter Phase III In Second Half

Firm reports first-quarter revenues of over $1 billion.

Merck Aims To Duplicate Januvia Launch Success In 2007

Launches for Janumet, Arcoxia and Emend IV are keys to continuing the momentum of firm’s turnaround plan, CEO Clark says.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

Partisan Politics Returns To US FDA Congressional Oversight

GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows

Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development

See All
UsernamePublicRestriction

Register

PS063527

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By